- Retrophin (RTRX) appoints Stephen Aselage President and COO effective immediately. He will be responsible for corporate development activities including the commercialization of current products, building out the firm's global infrastructure and exploring new business development opportunities.
- Mr. Aselage joined Retrophin in 2012 from BioMarin Pharmaceuticals where he was EVP and Chief Business Officer.
From other sites
at Zacks.com (Mar 19, 2015)
at Nasdaq.com (Nov 14, 2014)
at MarketWatch.com (Sep 16, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs